Paul Jackson

S&P 500 and Nasdaq Rise as Shutdown Threat Clouds Jobs Data

Stocks Edge Higher Despite Shutdown Jitters U.S. stocks mostly climbed Monday as investors weighed the rising odds of a government shutdown that could disrupt the release of critical economic data. The Department of Labor confirmed that the Bureau of Labor

Anthropic Launches Claude Sonnet 4.5, A Smarter ‘Colleague’

Claude Sonnet 4.5 Raises the Bar AI startup Anthropic unveiled its latest model, Claude Sonnet 4.5, on Monday, positioning it as the company’s most practical and business-ready system to date. The model excels in coding, computer usage, and workflow automation,

PG&E’s $73B Plan Signals AI-Driven Energy Crunch Ahead

PG&E Bets on an AI-Powered Future PG&E Corp (NYSE: PCG) announced it will invest $73 billion through 2030 to reinforce California’s transmission system as AI-fueled data centers drive unprecedented electricity demand. The utility said it expects to serve 10 gigawatts

OpenAI’s Trillion-Dollar Bet Redefines the AI Arms Race

A Historic Week for OpenAI OpenAI reshaped the AI arms race this week with a rapid-fire series of announcements that put hard numbers behind CEO Sam Altman’s trillion-dollar vision. Together, the deals cement OpenAI’s position as the anchor tenant of

Stocks Fall as GDP Jumps and Jobless Claims Decline

Markets Lose Momentum U.S. stocks pulled back Thursday as investors digested a mix of strong economic data and uncertainty about the Federal Reserve’s next move. Big Tech names led the decline, with Oracle (ORCL) extending losses and Tesla (TSLA) sliding

Tesla Sales Plunge 22% in Europe as Competition Heats Up

Tesla’s European Decline Deepens Tesla’s troubles in Europe worsened in August as sales fell 22.5% year over year, according to data from the European Automobile Manufacturers’ Association (ACEA). The company registered just 14,831 vehicles across the region, even as total

Eli Lilly to Build $6.5B Houston Plant for Obesity Pill Production

Eli Lilly Expands U.S. Manufacturing Footprint Eli Lilly (LLY) announced plans to build a $6.5 billion manufacturing facility in Houston, Texas, as the company accelerates its push into obesity and cardiometabolic treatments. The site will focus on producing small molecule

Subscribe